Edgestream Partners, L.P. Apellis Pharmaceuticals, Inc. Transaction History
Edgestream Partners, L.P.
- $3.32 Billion
- Q3 2025
A detailed history of Edgestream Partners, L.P. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Edgestream Partners, L.P. holds 129,751 shares of APLS stock, worth $2.64 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
129,751
Previous 218,392
40.59%
Holding current value
$2.64 Million
Previous $3.78 Million
22.33%
% of portfolio
0.09%
Previous 0.11%
Shares
7 transactions
Others Institutions Holding APLS
# of Institutions
328Shares Held
124MCall Options Held
4.12MPut Options Held
756K-
Avoro Capital Advisors LLC New York, NY12.2MShares$248 Million3.78% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.99MShares$203 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.64MShares$196 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.29MShares$189 Million0.04% of portfolio
-
Deep Track Capital, LP Greenwich, CT8MShares$163 Million5.71% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.23B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...